Antibody-drug combination therapy in cancer treatment

Abstract

Abstract Antibody-drug conjugates (ADCs) are a new generation of anticancer therapeutics with enhanced selectivity against the target cancer cells over the conventional chemotherapeutic agents. Such conjugates help in delivery of drugs with enhanced therapeutic performance, thus creating a highly target-specific and cytotoxic-anticancer therapy with the advantage of a wide therapeutic window. Several drug molecules have been investigated in this regard for improving their anticancer activity with the help of antibodies of specific targeting ability to the human cancers. ADCs also help in reducing the toxicity of chemotherapeutic agents by transforming them into the inactive agents.